immunotherapy — grants

Sort

48,018 grants matching “immunotherapy”

Epigenetic Regulation of Normal and Pathologic CTCF Functions by Paralogous CTCFL a.k.a. BORIS

$643,928

Victor Lobanenkov · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI

Immunotherapy Modeling in Organoids Co-preserving Tumor and Infiltrating Immune Compartments

$643,856

Calvin J Kuo · Stanford University · R01 · FY2023 · CA

Prebiotic effect of eicosapentaenoic acid treatment for colorectal cancer

$643,839

Andrew T Chan · Massachusetts General Hospital · R01 · FY2020 · CA

Structure-based inhibition of chemokine signaling in the inflamed pancreas

$643,818

Brian F Volkman · Medical College Of Wisconsin · R01 · FY2025 · DK

Development of quantitative optical tools to continuously monitor cerebral autoregulation, blood flow, oxygenation and inflammation during pediatric extracorporeal life support

$643,809

David Richard Busch · Ut Southwestern Medical Center · R01 · FY2023 · NS

Modeling the Molecular Determinants of Induced Anti-Tumor Immune Responses in Mantle Cell Lymphoma

$643,804

Arash Ash Alizadeh · Stanford University · U01 · FY2017 · CA

Serum biomarkers to predict immune related adverse events and benefit from single agent pembrolizumab therapy in early stage triple negative breast cancer

$643,798

Ji Qiu · Arizona State University-Tempe Campus · R01 · FY2025 · CA

Mechanisms controlling the persistence of infectious HIV reservoirs in children

$643,772

Lisa M Frenkel · Seattle Children'S Hospital · R01 · FY2020 · HD

Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients with Prostate Cancer

$643,764

Nupam P Mahajan · Washington University · R01 · FY2025 · CA

MR-Guided Focused Ultrasound Combined with Immunotherapy to Treat Malignant Brain Tumors

$643,560

Max Wintermark · Stanford University · R01 · FY2018 · CA

Immunotherapy Modeling in Organoids Co-preserving Tumor and Infiltrating Immune Compartments

$643,552

Calvin J Kuo · Stanford University · R01 · FY2022 · CA

Development of a New Multiplexed Imaging Strategy for Immunoprofiling using Raman-Active Nanoparticles

$643,522

Cristina L. Zavaleta · University Of Southern California · R01 · FY2024 · CA

Preclinical development and clinical monitoring of adoptive immune therapy

$643,479

Frances Hakim · Division Of Basic Sciences - Nci · ZIC · FY2016 · CA

City of Hope Clinical Oncology Career Research Development Program

$643,198

Joanne E. Mortimer · Beckman Research Institute/City Of Hope · K12 · FY2011 · CA

Chemokine-mediated antigen-specific T cell responses and immunotherapies to treat head and neck cancer

$643,133

Dohun Pyeon · Michigan State University · R01 · FY2024 · DE

Exploiting A Critical Vulnerability To Glutamine Antimetabolite Therapy in Fibrolamellar Hepatocellular Carcinoma (FLC)

$643,101

Mark Yarchoan · Johns Hopkins University · R01 · FY2025 · CA

Identification of REV-ERB inverse agonists for cancer immunotherapy

$643,014

Laura A Solt · Scripps Florida · R01 · FY2020 · CA

The effects of PD-1 on tumor-mediated âemergencyâ myelopoiesis and fate commitment of myeloid cells: Implications for anti-tumor immunity

$642,962

Vassiliki A Boussiotis · Beth Israel Deaconess Medical Center · R01 · FY2020 · CA

PRETARGETING WITH ANTI-CEA MABS FOR THERAPY

$642,945

Paul Yazaki · Beckman Research Institute/City Of Hope · P01 · FY2009 · CA

Epigenetic Regulation of Normal and Pathologic CTCF Functions by Paralogous CTCFL a.k.a. BORIS

Immunotherapy Modeling in Organoids Co-preserving Tumor and Infiltrating Immune Compartments

Prebiotic effect of eicosapentaenoic acid treatment for colorectal cancer

Structure-based inhibition of chemokine signaling in the inflamed pancreas

Development of quantitative optical tools to continuously monitor cerebral autoregulation, blood flow, oxygenation and inflammation during pediatric extracorporeal life support

Modeling the Molecular Determinants of Induced Anti-Tumor Immune Responses in Mantle Cell Lymphoma

Serum biomarkers to predict immune related adverse events and benefit from single agent pembrolizumab therapy in early stage triple negative breast cancer

Mechanisms controlling the persistence of infectious HIV reservoirs in children

Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients with Prostate Cancer

Cerebral amyloid angiopathy fluid biomarkers evaluation (CAFE)

BAFF-R CAR T cell therapy for ALL

Synthetic rescue of antigen-driven T cells and alloimmunity

Translation of a novel combination therapy approach for non-Hodgkin lymphoma

Mechanisms of impaired T-cell mechanosensing of melanoma antigens

Gene Regulatory Events in Establishing Mature T Cell Tolerance

MR-Guided Focused Ultrasound Combined with Immunotherapy to Treat Malignant Brain Tumors

Immunotherapy Modeling in Organoids Co-preserving Tumor and Infiltrating Immune Compartments

Development of a New Multiplexed Imaging Strategy for Immunoprofiling using Raman-Active Nanoparticles

Preclinical development and clinical monitoring of adoptive immune therapy

City of Hope Clinical Oncology Career Research Development Program

Chemokine-mediated antigen-specific T cell responses and immunotherapies to treat head and neck cancer

Exploiting A Critical Vulnerability To Glutamine Antimetabolite Therapy in Fibrolamellar Hepatocellular Carcinoma (FLC)

Identification of REV-ERB inverse agonists for cancer immunotherapy

The effects of PD-1 on tumor-mediated âemergencyâ myelopoiesis and fate commitment of myeloid cells: Implications for anti-tumor immunity

PRETARGETING WITH ANTI-CEA MABS FOR THERAPY

The effects of PD-1 on tumor-mediated âemergencyâ myelopoiesis and fate commitment of myeloid cells: Implications for anti-tumor immunity